BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BioCentury | Aug 17, 2018
Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
BC Innovations | Nov 9, 2017
Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...
BC Week In Review | Oct 6, 2017
Company News

BridgeBio launches SHP-2 inhibitor play Navire

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Navire Pharma Inc. , a subsidiary aimed at treating genetically driven, treatment-resistant cancer, with a $30 million investment. Navire plans to start clinical testing of its Src homology protein...
BC Extra | Oct 4, 2017
Financial News

BridgeBio unveils SHP-2 inhibitor play Navire

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Navire Pharma Inc. , a subsidiary aimed at treating genetically driven, treatment-resistant cancer, with a $30 million investment. Navire plans to start clinical testing of its Src homology protein...
Items per page:
1 - 6 of 6
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BioCentury | Aug 17, 2018
Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
BC Innovations | Nov 9, 2017
Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...
BC Week In Review | Oct 6, 2017
Company News

BridgeBio launches SHP-2 inhibitor play Navire

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Navire Pharma Inc. , a subsidiary aimed at treating genetically driven, treatment-resistant cancer, with a $30 million investment. Navire plans to start clinical testing of its Src homology protein...
BC Extra | Oct 4, 2017
Financial News

BridgeBio unveils SHP-2 inhibitor play Navire

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Navire Pharma Inc. , a subsidiary aimed at treating genetically driven, treatment-resistant cancer, with a $30 million investment. Navire plans to start clinical testing of its Src homology protein...
Items per page:
1 - 6 of 6